Sidoti Forecasts Prenetics Global’s Q3 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Research analysts at Sidoti issued their Q3 2026 earnings estimates for shares of Prenetics Global in a report released on Monday, June 22nd. Sidoti analyst A. Hantman anticipates that the company will post earnings of ($0.48) per share for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.77) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $1.21 EPS and FY2027 earnings at $1.89 EPS.

Several other analysts have also commented on PRE. Benchmark began coverage on shares of Prenetics Global in a report on Tuesday, June 16th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a report on Tuesday, April 21st. Finally, Lake Street Capital started coverage on Prenetics Global in a research report on Monday, March 16th. They issued a “buy” rating and a $29.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.75.

Prenetics Global Price Performance

Shares of NASDAQ PRE opened at $19.92 on Wednesday. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63. The company’s 50-day moving average is $18.41 and its 200 day moving average is $18.17. The stock has a market capitalization of $336.05 million, a P/E ratio of -4.35 and a beta of 0.24.

Prenetics Global (NASDAQ:PRE) last issued its quarterly earnings data on Wednesday, June 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.07). Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%.The company had revenue of $35.95 million during the quarter, compared to the consensus estimate of $36.00 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN purchased a new stake in shares of Prenetics Global in the fourth quarter worth $47,000. State of Wyoming purchased a new position in shares of Prenetics Global in the 1st quarter worth about $48,000. JPMorgan Chase & Co. purchased a new position in shares of Prenetics Global in the 3rd quarter worth about $65,000. Manatuck Hill Partners LLC bought a new position in Prenetics Global in the 4th quarter worth about $170,000. Finally, T3 Companies LLC purchased a new stake in Prenetics Global during the 4th quarter valued at about $170,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

Prenetics Global announced that its board has authorized a share repurchase plan on Friday, March 6th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the company to purchase up to 15.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.